The Dutch Working Party on Antibiotic Policy (SWAB) has developed an evidence-based guideline for the treatment of invasive fungal infections in adults and children.

Voriconazole is the preferred treatment for patients with invasive aspergillosis.

The treatment of candidemia and invasive candidiasis is based upon the severity of illness and the likelihood of fluconazole resistance.

Patients with a moderately severe to severe illness and patients with a risk of fluconazole resistant Candida species, are primarily treated with anidulafungin or caspofungin.

In the case of stable patients, the treatment can usually be continued with oral fluconazole or voriconazole.

Less severely ill patients, without risk of a fluconazole resistant Candida species, are initially treated with fluconazole.

Patients with cryptococcal meningitis should be treated with amphotericin B and flucytosine. In patients with a favourable response transition to fluconazole is possible after 2 weeks.